

YOUR RELIABLE PARTNER  
IN A BIODISCOVERY PROCESS

## COMPANY OVERVIEW

### IN VITRO ANTIBODY AND APTAMER SELECTION

- Proprietary libraries of high quality
- Extensive expertise
- Risk-sharing policy
- Opportunities for partnering



### PROTEIN ENGINEERING AND CHARACTERIZATION

- Experts in difficult proteins
- Proven track record in protein formulation and characterization
- Broad portfolio of techniques used
- Multiple partners worldwide

### COMMITMENT TO QUALITY

- Dedicated project manager and custom approach to each project
- Highest standards of confidentiality
- ISO 17025 and GLP-compliant research
- LIMS-enabled laboratory



## PURE SELECT


A human recombinant monoclonal antibody selection platform against custom molecular targets, including whole cells.

Our proprietary technology allows for in vitro selection of high-affinity human recombinant antibodies against practically any antigen, including whole-cell immunization. Following the primary selection of interacting clones, an affinity maturation library can be constructed to further enhance antigen-binding affinity. Finally, the selected antibody fragments can be converted (using recombinant DNA technology) into other antibody formats, including: full IgG molecule, Fab or scFv dimer, and further chemically functionalized to give rise to a drug lead candidate, an antibody drug conjugate (ADC), or molecular diagnostic tool, such as a fluorescent labeled probe.




## PURE SELECT 2

- Proprietary E. coli strains for efficient selection and antibody production
- Modified helper phage for highly efficient antibody display
- High-quality library of variants (no stop codons, no empty variants, stability conditioning)
- HT panels for optimization of production & formulation conditions
- Variety of available antibody formats
- Fast selection procedure



## PURE SELECT 2 AVAILABLE IN 2019

- Contact us for more details!



## PURE APTA

We have developed a proprietary PureApta platform for the in vitro selection of chemically modified aptamers.

We provide modified and unmodified aptamers selection services against your selected molecular target (protein, small molecule), comprising:

- The selection using PureApta platform
- NGS sequencing of the whole selection pool
- Proprietary bioIT analysis to select best aptamers candidate families
- Thorough aptamers validation and optimization using several orthogonal biophysical binding assays, depending on your planned application


## WHY PURE APTA?

- Broad portfolio of chemical modifications to improve binding potential and nuclease resistance
- On-demand custom modifications to fit exactly your target
- Advanced techniques to provide high selection success chance
- Clones validation using orthogonal biophysical assays (e.g. SPR, BLI)
- Customized projects to adapt to your application requirements

## RECOMBINANT PROTEIN

### OUR ADVANCED SOLUTIONS FOR RECOMBINANT PROTEINS

We have developed a comprehensive portfolio of services comprising the production, refolding, purification, formulation and analysis of native and recombinant proteins, as well as a supplementary platform for assay development. Taken together we offer a whole range of contract research services to accelerate your projects.



IN VITRO ANTIBODY AND APTAMER SELECTION • DRUG DEVELOPMENT  
PROTEIN EXPRESSION AND PURIFICATION • CHALLENGING PROTEINS



#### Headquarters:

Pure Biologics Inc.  
Dunska 11, 54-427, Wroclaw, Poland  
+48 570 00 28 29  
+1 415 830 6341  
info@purebiologics.com

#### German Branch:

Rudower Chaussee 29, 12489 Berlin  
+49 30 208 475 89  
berlin@purebiologics.com